[go: up one dir, main page]

AR011411A1 - Composicion de fenofibrato de liberacion inmediata, metodo para prepararla y suspension de fenofibrato en forma micronizada. - Google Patents

Composicion de fenofibrato de liberacion inmediata, metodo para prepararla y suspension de fenofibrato en forma micronizada.

Info

Publication number
AR011411A1
AR011411A1 ARP980100155A ARP980100155A AR011411A1 AR 011411 A1 AR011411 A1 AR 011411A1 AR P980100155 A ARP980100155 A AR P980100155A AR P980100155 A ARP980100155 A AR P980100155A AR 011411 A1 AR011411 A1 AR 011411A1
Authority
AR
Argentina
Prior art keywords
phenofibrate
suspension
preparing
micronized form
fenofibrate
Prior art date
Application number
ARP980100155A
Other languages
English (en)
Original Assignee
Fournier Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9502710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011411(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fournier Lab Sa filed Critical Fournier Lab Sa
Publication of AR011411A1 publication Critical patent/AR011411A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composicion de liberacion inmediata de fenofibrato, que consiste en (a) un portador hidrosoluble inerte cubierto por, como mínimo, una capa quecontiene fenofibrato, en una forma micronizada que tiene un tamano inferior a 20 micrones; unpolímer o hidrofilo y como opcion, un tensioactivo, el dichopolímero constituyendo, como mínimo, el 20% en peso de (a); y (b), como opcion, una fase o capa exterior, o varias fases o capas exteriores. Un método parapreparar una composicionfarmacéutica segun una cualquiera de las reivindicaciones precedentes, el método caracterizado por las etapas de: (a)preparar una suspension de fenofibrato en forma micronizada, con un tamano de partícula inferior a los 20 micrones,en una solucion de polímero hidrofilo y,como opcion, tensioactivo; (b) aplicar la suspension de la etapa (a), a un portador inerte hidrosoluble, (c) como opcion, revestir los granulos asíobtenidos con una fase o capa, o varias de ellas.
ARP980100155A 1997-01-17 1998-01-14 Composicion de fenofibrato de liberacion inmediata, metodo para prepararla y suspension de fenofibrato en forma micronizada. AR011411A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9700479A FR2758459B1 (fr) 1997-01-17 1997-01-17 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation

Publications (1)

Publication Number Publication Date
AR011411A1 true AR011411A1 (es) 2000-08-16

Family

ID=9502710

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100155A AR011411A1 (es) 1997-01-17 1998-01-14 Composicion de fenofibrato de liberacion inmediata, metodo para prepararla y suspension de fenofibrato en forma micronizada.

Country Status (35)

Country Link
US (18) US6074670A (es)
EP (6) EP1275387B1 (es)
JP (6) JP4219988B2 (es)
KR (2) KR100415897B1 (es)
CN (2) CN1496738B (es)
AR (1) AR011411A1 (es)
AT (4) ATE233556T1 (es)
BR (1) BR9806738A (es)
CA (4) CA2372576C (es)
CY (4) CY2396B1 (es)
CZ (1) CZ297251B6 (es)
DE (5) DE69832108T2 (es)
DK (5) DK1273294T3 (es)
DZ (1) DZ2398A1 (es)
EE (1) EE04042B1 (es)
EG (1) EG23978A (es)
ES (5) ES2195308T3 (es)
FR (1) FR2758459B1 (es)
HU (3) HU230685B1 (es)
ID (1) ID22528A (es)
IL (1) IL130790A0 (es)
IN (1) IN187906B (es)
IS (1) IS5097A (es)
MA (1) MA26466A1 (es)
NO (2) NO329200B1 (es)
NZ (1) NZ336462A (es)
PL (1) PL194802B1 (es)
PT (4) PT952829E (es)
RU (3) RU2196580C2 (es)
SK (1) SK285847B6 (es)
TN (1) TNSN98009A1 (es)
TR (1) TR199901660T2 (es)
UA (1) UA61096C2 (es)
WO (1) WO1998031361A1 (es)
ZA (1) ZA98324B (es)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SK288117B6 (sk) * 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
CA2270306C (en) * 1999-04-27 2000-09-26 Bernard Charles Sherman Pharmaceutical compositions comprising co-micronized fenofibrate
US6465011B2 (en) * 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368620B2 (en) 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
EP1364643A4 (en) * 2000-12-01 2009-07-15 Kyowa Hakko Kogyo Kk COMPOSITION WITH IMPROVED SOLUBILITY OR ORAL ABSORBIBILITY
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
ATE331512T1 (de) 2001-01-26 2006-07-15 Schering Corp Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
MEP27808A (en) 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ES2284646T3 (es) * 2001-02-22 2007-11-16 Jagotec Ag Combinaciones de estatina-fibrato con efectos secundarios en ayunas-alimentado reducidos.
US7189412B2 (en) * 2001-03-01 2007-03-13 Aska Pharmaceutical Co., Ltd. Fenofibrate-containing composition
CN101961317A (zh) * 2001-07-06 2011-02-02 生命周期药物公司 受控制的凝聚
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
EP2085072A1 (en) * 2002-03-26 2009-08-05 Teva Pharmaceutical Industries Ltd. Drug microparticles
AU2003225285A1 (en) * 2002-05-03 2003-11-17 Skyepharma Canada Inc. Oral dosage forms comprising fenofibrate
US6828334B2 (en) * 2002-05-23 2004-12-07 Usv Limited Fenofibrate-cyclodextrin inclusion complexes and their pharmaceutical composition
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
WO2004002458A1 (en) * 2002-06-28 2004-01-08 Shire Laboratories Inc. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
EP2295529B2 (en) 2002-07-11 2022-05-18 Basf As Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
SE0202188D0 (sv) * 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
AU2003263480A1 (en) * 2002-09-24 2004-04-19 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of fenofibrate having high bioavailability
JP5404990B2 (ja) * 2002-10-23 2014-02-05 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリアに対するワクチン接種の方法
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CN100367947C (zh) * 2002-12-04 2008-02-13 徐州恩华赛德药业有限责任公司 具有抗高血脂症的含非诺贝特的药物组合物
CA2509101A1 (en) 2002-12-13 2004-07-01 Jagotec Ag A topical nanoparticulate spironolactone formulation
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
RU2356549C2 (ru) * 2002-12-17 2009-05-27 Эббетт ГмбХ унд Ко.КГ Композиция, включающая фенофибриновую кислоту, ее физиологически приемлемую соль или производное
US20040142903A1 (en) * 2003-01-16 2004-07-22 Par Pharmaceutical Inc. Bioavailable fenofibrate compositions, methods for treating hyperlipidemia and hypercholesterolemia and processes for the preparation of such compositions
US20040162320A1 (en) * 2003-02-14 2004-08-19 Pawan Seth Solid composition containing nisoldipine a mixture of polyethylene oxides and an antioxidant
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1606287B1 (en) * 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004108126A1 (en) * 2003-06-06 2004-12-16 Snowden Pharmaceuticals, Llc Fibric acid derivatives for the treatment of irritable bowel syndrome
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
ATE540671T1 (de) 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
RU2343905C2 (ru) * 2003-10-10 2009-01-20 Лайфсайкл Фарма А/С Твердые дозированные формы, включающие фибрат и статин
KR20130103818A (ko) * 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
DE102004002761B4 (de) * 2004-01-20 2017-01-05 Daimler Ag Verfahren zum Betrieb eines Antriebsstrangs eines Kraftfahrzeugs
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
FR2868079B1 (fr) * 2004-03-29 2007-06-08 Seppic Sa Tensioactifs sous forme de poudre utilisables dans des comprimes ou des gelules procede de preparation et compositions les contenant
US7244765B2 (en) 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8026281B2 (en) * 2004-10-14 2011-09-27 Lupin Atlantis Holdings, S.A. Treating metabolic syndrome with fenofibrate
WO2006060817A1 (en) * 2004-12-03 2006-06-08 Abbott Laboratories Pharmaceutical compositions
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
KR20070098855A (ko) * 2004-12-06 2007-10-05 릴라이언트 파마슈티컬스 인코퍼레이티드 지방산 에스테르와 페노피브레이트의 안정한 조성물
AU2005314361B2 (en) * 2004-12-06 2012-04-12 Glaxosmithkline Llc Omega-3 fatty acids and dyslipidemic agent for lipid therapy
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
WO2006076508A2 (en) * 2005-01-14 2006-07-20 Avax Technologies, Inc. Method for producing a vaccine for the treatment of cancer
KR20070094666A (ko) * 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
JP2006273849A (ja) * 2005-03-02 2006-10-12 Aska Pharmaceutical Co Ltd フェノフィブラート含有組成物
CA2600429A1 (en) * 2005-03-08 2006-09-14 Reliant Pharmaceuticals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
KR20070119700A (ko) * 2005-03-30 2007-12-20 테바 파마슈티컬 인더스트리즈 리미티드 페노피브레이트 및 계면 활성제 혼합물을 함유하는 제제
EP1707197A1 (en) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
KR20070113289A (ko) * 2005-03-30 2007-11-28 테바 파마슈티컬 인더스트리즈 리미티드 멘톨 또는 ｐｅｇ/폴록사머를 함유하는 개선된페노피브레이트 제제
US20070148234A1 (en) * 2005-04-08 2007-06-28 Ju Tzuchi R Pharmaceutical formulations
WO2006135480A2 (en) 2005-04-08 2006-12-21 Abbott Laboratories Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
US20070185199A1 (en) * 2005-04-08 2007-08-09 Ju Tzuchi R Pharmaceutical formulations
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
JP2008540644A (ja) * 2005-07-15 2008-11-20 テバ ファーマシューティカル インダストリーズ リミティド 新規粒質化方法及びそれから生成される粒質物
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
EP1785133A1 (en) 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
PL1803441T3 (pl) 2005-12-28 2009-10-30 Teva Pharma Farmaceutyczne formulacje fenofibratu o polepszonej biodostępności
JP2009522258A (ja) * 2005-12-28 2009-06-11 テバ ファーマシューティカル インダストリーズ リミティド 増大したバイオアベイラビリティを有するフェノフィブラートの医薬製剤
JP2009537478A (ja) * 2006-05-13 2009-10-29 ノヴォ ノルディスク アクティーゼルスカブ レパグリニドとメトホルミンを含む錠剤配合物
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
US20080050450A1 (en) * 2006-06-26 2008-02-28 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US9308175B2 (en) 2006-09-15 2016-04-12 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
US20100034888A1 (en) * 2006-09-15 2010-02-11 Hubert Clemens Pellikaan Granulate containing a pharmaceutically active substance and method for its manufacture
KR20090067210A (ko) * 2006-10-13 2009-06-24 얀센 파마슈티카 엔.브이. 페닐알킬 카바메이트 조성물
US20110097414A1 (en) * 2007-02-26 2011-04-28 Sandal Roshan Lal Pharmaceutical compositions comprising adsorbate of fenofibrate
WO2008109018A1 (en) * 2007-03-02 2008-09-12 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
US7872560B2 (en) * 2007-03-19 2011-01-18 Abc Taiwan Electronics Corp. Independent planar transformer
SI2489731T1 (sl) 2007-07-26 2014-12-31 Amgen Inc. Patent Operations, M/S 28-2-C Modificirani encimi lecitin-holesterol aciltransferaze
US20100285126A1 (en) * 2007-08-02 2010-11-11 Rahul Dabre Pharmaceutical compositions of fenofibrate
CA2700426C (en) 2007-09-25 2017-10-31 Galia Temtsin Krayz Compositions comprising lipophilic active compounds and method for their preparation
US20090202649A1 (en) * 2008-02-06 2009-08-13 Subhash Gore Fenofibrate formulations
KR101569227B1 (ko) 2008-03-11 2015-11-13 아스카 세이야쿠 가부시키가이샤 고체 분산체와 그 의약 조성물, 그리고 그들의 제조 방법
MX2011006307A (es) 2008-12-15 2011-10-14 Banner Pharmacaps Inc Metodos para aumentar la liberacion y absorcion de agentes activos insolubles en agua.
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
FR2940118B1 (fr) 2008-12-24 2013-08-09 Ethypharm Sa Formulation pharmaceutique de fenofibrate nanonise
AU2009334794B2 (en) 2009-01-02 2014-12-04 Bgp Products Ireland Limited Novel use of fibrates
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010092925A1 (ja) * 2009-02-12 2010-08-19 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
NZ596610A (en) * 2009-05-27 2014-04-30 Samyang Biopharmaceuticals A poorly soluble drug containing microsphere with improved bioavailability and method of preparing the same
US20110217369A1 (en) * 2009-09-03 2011-09-08 Ranbaxy Laboratories Limited Fenofibrate compositions
KR100980752B1 (ko) * 2009-12-17 2010-09-07 삼일제약주식회사 담체 표면 상에 흡착된 페노피브레이트를 포함하는 과립 및 이를 포함하는 약학 조성물
KR101202994B1 (ko) 2010-04-12 2012-11-21 한미사이언스 주식회사 페노피브린산 및 알칼리화제를 포함하는 경구용 약학 조성물
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US10192644B2 (en) 2010-05-11 2019-01-29 Lightbridge Corporation Fuel assembly
WO2011143172A1 (en) 2010-05-11 2011-11-17 Thorium Power, Inc. Fuel assembly with metal fuel alloy kernel and method of manufacturing thereof
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
GB201118182D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
WO2013064853A1 (en) 2011-11-05 2013-05-10 Lupin Atlantis Holdings, S.A. Reduced dose oral pharmaceutical compositions of fenofibrate
AU2012347540A1 (en) 2011-12-08 2014-06-26 Amgen Inc. Agonistic human LCAT antigen binding proteins and their use in therapy
US9452107B2 (en) 2012-04-16 2016-09-27 New Jersey Institute Of Technology Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
US8722083B2 (en) * 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate
EP2842547A1 (en) 2013-08-27 2015-03-04 Freund Pharmatec Ltd. Improved fenofibrate compositions
KR102171567B1 (ko) 2013-09-18 2020-10-29 조지타운 유니버시티 페노피브레이트 및 이의 유사체로 신경변성 질병을 치료하는 방법
KR101576587B1 (ko) * 2014-02-05 2015-12-10 한양대학교 에리카산학협력단 신규한 페노피브레이트 함유 젤라틴 나노입자
PL3154528T3 (pl) 2014-06-11 2023-07-10 SpecGx LLC Suszone rozpyłowo kompozycje o różnych profilach rozpuszczania i sposoby ich wytwarzania
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CN104352466A (zh) * 2014-11-17 2015-02-18 辰欣药业股份有限公司 一种非诺贝特组合物及其制剂
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CN104922078B (zh) * 2015-06-23 2018-10-23 上海市计划生育科学研究所 非诺贝特迟释微丸、制备方法及应用
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
CN107049981A (zh) * 2017-04-11 2017-08-18 深圳市泛谷药业股份有限公司 一种速释氨磺必利药物组合物及其制备方法
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
SG11202008435SA (en) * 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
EP3824296A4 (en) 2018-07-20 2022-04-27 Lipocine Inc. LIVER DISEASE
US20220273652A1 (en) 2019-07-31 2022-09-01 Intas Pharmaceuticals Ltd. Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate
EP3943071B1 (de) 2020-03-31 2025-06-18 Zurab Durmischchanowitch Khinikadze Zusammensetzung, enthaltend natürliche lipophile verbindungen, verwendung der zusammensetzung und verfahren zur herstellung der zusammensetzung
KR102489384B1 (ko) * 2020-09-29 2023-01-18 애드파마 주식회사 생체이용율이 개선된 페노피브레이트 입자를 포함하는 약제학적 조성물
JP2025530005A (ja) 2022-09-15 2025-09-09 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物
CN119700739B (zh) * 2025-02-26 2025-06-20 中国人民解放军总医院第三医学中心 非诺贝特在治疗Fuchs角膜内皮营养不良中的应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58004A (en) * 1866-09-11 Improved lap-joint for belting
US57999A (en) * 1866-09-11 Improved composition for roofing
US9496A (en) * 1852-12-21 Method of measuring cloth on the cloth-beam
US6655A (en) * 1849-08-21 Eirepboof safe
US104060A (en) * 1870-06-07 Improvement in organ-bellows
US5783A (en) * 1848-09-19 Spinoabdominal supporter
US57997A (en) * 1866-09-11 Improvement in malt-ksln floors
US104051A (en) * 1870-06-07 Improvement in handles of sheet-metal spoons, forks
US57998A (en) * 1866-09-11 Improvement in broom-heads
US168413A (en) * 1875-10-05 Improvement in hydrants
US92597A (en) * 1869-07-13 Improved counterpoise gun-carriage
US58005A (en) * 1866-09-11 Improvement in distilling petroleum and other liquids
US114839A (en) * 1871-05-16 Improvement in apparatus for aerating beer-barrels
US2953497A (en) * 1953-06-03 1960-09-20 Howard A Press Therapeutic tablets
US2776996A (en) * 1955-12-22 1957-01-08 Du Pont Manufacture of beta-methylmercaptopropionaldehyde
CH543472A (fr) 1969-01-31 1973-10-31 Orchimed Sa Procédé pour la préparation d'acides phénoxyalcoyl-carboxyliques
FR2314917A1 (fr) * 1975-06-20 1977-01-14 Rhone Poulenc Ind Procede de fabrication de l'aldehyde beta-methylthiopropionique
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
EP0012523B2 (en) 1978-11-20 1988-02-03 American Home Products Corporation Therapeutic compositions with enhanced bioavailability and process for their preparation
FR2494112B1 (es) * 1980-11-19 1986-01-10 Laruelle Claude
DE3107933A1 (de) * 1981-03-02 1982-09-16 Cassella Ag, 6000 Frankfurt Substituierte 3-amino-sydnonimine, verfahren zu ihrer herstellung und ihre verwendung
ZA822995B (en) * 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4463743A (en) * 1981-12-14 1984-08-07 Brunswick Corporation Capacitor discharge ignition system for internal combustion engines
FR2532706B1 (fr) * 1982-09-07 1987-04-30 Renault Dispositif d'amortissement et vibrations d'un coupleur elastique en milieu humide, en particulier pour convertisseur de couple
DE3247118A1 (de) * 1982-12-20 1984-06-20 Cassella Ag, 6000 Frankfurt Neue substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
FR2557459B1 (fr) * 1984-01-02 1986-05-30 Lhd Lab Hygiene Dietetique Matrice inerte a base de polycaprolactone pour administration orale d'un medicament, et procede de preparation de la forme galenique comprenant cette matrice
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
IT1180507B (it) 1984-06-29 1987-09-23 Roberto Valducci Procedimento per la preparazione di etofibrato o sostanze di pari o simili caratteristiche, in microgunuli-ritardo e prodotto ottenuto con tale procedimento
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
EP0179583A1 (en) 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US4649082A (en) 1985-03-07 1987-03-10 Ppg Industries, Inc. Radiation curable compositions based on radiation curable esters of polyfunctional hydroxyl-containing carboxylic acids
US4716033A (en) * 1986-03-27 1987-12-29 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
CH668553A5 (de) * 1987-02-02 1989-01-13 Mepha Ag Arzneimittel mit verzoegerter wirkstofffreisetzung.
US4859703A (en) * 1987-06-15 1989-08-22 Warner-Lambert Company Lipid regulating compositions
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US4961891A (en) * 1988-10-04 1990-10-09 Garlock, Inc. Method of making high compressibility gasket material
US4927639A (en) * 1989-02-02 1990-05-22 Warner-Lambert Company Modified release gemfibrozil composition
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
GB9015872D0 (en) * 1990-07-19 1990-09-05 Secr Defence Production of ceramic filaments
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0519144B1 (en) * 1991-06-21 1997-08-13 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. New galenic process for omeprazole containing pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IT1264020B (it) * 1993-01-28 1996-09-09 Recordati Chem Pharm Procedimento per la preparazione di microgranuli idonei alla sospensione in liquidi
US5905171A (en) * 1995-06-22 1999-05-18 Novus International, Inc. Process for the preparation of 3-(methylthio)propanal
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
FR2723536A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Composition permettant une liberation selective d'un principe actif
FR2723586A1 (fr) 1994-08-11 1996-02-16 Seth Pawan Nouvelles compositions contenant de la cimetidine et associations en derivant
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
WO1997012581A2 (en) * 1995-09-21 1997-04-10 Pharma Pass L.L.C. Novel composition containing an acid-labile omeprazole and process for its preparation
DE19608750A1 (de) * 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Verfahren zur Herstellung von Fenofibrat-Präparaten
US6048547A (en) * 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
US5952396A (en) * 1997-06-16 1999-09-14 Raychem Corporation Low modulus elastomer
CA2214895C (en) * 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US6334192B1 (en) * 1998-03-09 2001-12-25 Ronald S. Karpf Computer system and method for a self administered risk assessment
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6180138B1 (en) 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6368622B2 (en) 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
GB2363866B (en) * 2000-05-31 2002-11-06 Intamission Ltd Data processing apparatus, method and system
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
ATE430567T1 (de) * 2000-09-29 2009-05-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine amidgruppe zur behandlung von malaria
DE60210626T2 (de) 2001-08-07 2007-03-15 Laboratoires Smb Sa Verbesserte pharmazeutische zusammensetzung mit einem ppar-alpha-mittel und verfahren zu ihrer herstellung
EP1414496B1 (en) * 2001-08-07 2010-10-20 Galephar M/F Pharmaceutical composition containing a combinaition of ppar-alpha, pravastatin and polyglycolized glyceride

Also Published As

Publication number Publication date
DK1275387T3 (da) 2006-08-28
CN1278678C (zh) 2006-10-11
US20040057998A1 (en) 2004-03-25
US20070190136A1 (en) 2007-08-16
US6277405B1 (en) 2001-08-21
DE69811855D1 (de) 2003-04-10
IN187906B (es) 2002-07-20
EG23978A (fr) 2008-02-26
EP1468681A1 (fr) 2004-10-20
CA2448623A1 (fr) 1998-07-17
IL130790A0 (en) 2001-01-28
US20020009496A1 (en) 2002-01-24
EP2050445B2 (fr) 2021-07-21
RU2196580C2 (ru) 2003-01-20
CA2372561A1 (fr) 1998-07-17
CA2219475C (fr) 2002-07-09
ES2241931T3 (es) 2005-11-01
US20030104060A1 (en) 2003-06-05
CZ253599A3 (cs) 1999-11-17
PL194802B1 (pl) 2007-07-31
HK1065952A1 (en) 2005-03-11
CY2547B1 (fr) 2008-07-02
US6074670A (en) 2000-06-13
ES2427252T5 (es) 2022-02-14
PT2050445E (pt) 2013-08-23
KR20000070021A (ko) 2000-11-25
HU227758B1 (hu) 2012-02-28
JP4943975B2 (ja) 2012-05-30
KR100391104B1 (ko) 2003-07-12
US7041319B2 (en) 2006-05-09
DK1273294T3 (da) 2006-03-13
CY2396B1 (en) 2004-09-10
ES2254569T3 (es) 2006-06-16
US20020114839A1 (en) 2002-08-22
EP1275387B1 (fr) 2006-05-03
US20040057997A1 (en) 2004-03-25
UA61096C2 (uk) 2003-11-17
CN1243438A (zh) 2000-02-02
ID22528A (id) 1999-10-28
US6589552B2 (en) 2003-07-08
EP2050445A3 (fr) 2009-09-09
CA2372576C (fr) 2004-02-10
AU731964B2 (en) 2001-04-05
TR199901660T2 (xx) 1999-09-21
RU2238089C2 (ru) 2004-10-20
DE69832108D1 (de) 2005-12-01
PT1275387E (pt) 2006-08-31
DK0952829T3 (da) 2003-06-23
ES2263714T3 (es) 2006-12-16
EP0952829B1 (fr) 2003-03-05
EP2050445A2 (fr) 2009-04-22
EP2050445B1 (fr) 2013-06-26
ATE324885T1 (de) 2006-06-15
WO1998031361A1 (fr) 1998-07-23
CA2448630A1 (fr) 1998-07-17
BR9806738A (pt) 2000-02-29
NO329200B1 (no) 2010-09-13
PL334748A1 (en) 2000-03-13
HK1131051A1 (en) 2010-01-15
DE29825080U1 (de) 2004-11-04
NO993519D0 (no) 1999-07-16
DE69829591T2 (de) 2006-02-09
US20040092597A1 (en) 2004-05-13
US20030104051A1 (en) 2003-06-05
HU0400409D0 (hu) 2004-04-28
JP4219988B2 (ja) 2009-02-04
JP2001511156A (ja) 2001-08-07
DK2050445T4 (da) 2021-10-18
CA2219475A1 (fr) 1998-07-17
EP0952829A1 (fr) 1999-11-03
HU230685B1 (en) 2017-08-28
EE9900296A (et) 2000-02-15
CA2372576A1 (fr) 1998-07-17
RU2236850C2 (ru) 2004-09-27
HUP0000808A3 (en) 2001-02-28
JP2005206614A (ja) 2005-08-04
US20040058005A1 (en) 2004-03-25
US20040057999A1 (en) 2004-03-25
EP1275387A1 (fr) 2003-01-15
JP4365343B2 (ja) 2009-11-18
NZ336462A (en) 2000-09-29
US6652881B2 (en) 2003-11-25
CZ297251B6 (cs) 2006-10-11
DE69811855T2 (de) 2003-12-18
EP1273293A1 (fr) 2003-01-08
DE69834437T2 (de) 2006-11-16
DE69834437D1 (de) 2006-06-08
RU2002109746A (ru) 2004-03-20
HU228849B1 (hu) 2013-06-28
ZA98324B (en) 1998-08-12
DE69829591D1 (de) 2005-05-04
US20080064759A1 (en) 2008-03-13
JP2011173927A (ja) 2011-09-08
ES2427252T3 (es) 2013-10-30
DK1273293T3 (da) 2005-06-27
US8343540B2 (en) 2013-01-01
EE04042B1 (et) 2003-06-16
SK285847B6 (sk) 2007-09-06
US7037529B2 (en) 2006-05-02
JP2009120623A (ja) 2009-06-04
PT1273293E (pt) 2005-06-30
CN1496738B (zh) 2011-03-30
JP2009143967A (ja) 2009-07-02
CY2513B1 (en) 2005-12-23
SK96299A3 (en) 2000-08-14
IS5097A (is) 1999-06-29
FR2758459A1 (fr) 1998-07-24
US6596317B2 (en) 2003-07-22
NO20100034L (no) 1999-09-16
JP2007326878A (ja) 2007-12-20
EP1273293B1 (fr) 2005-03-30
DE69832108T2 (de) 2006-09-21
HUP0000808A2 (hu) 2000-12-28
KR100415897B1 (ko) 2004-01-24
US20040058004A1 (en) 2004-03-25
AU5336798A (en) 1998-08-07
US20090035379A1 (en) 2009-02-05
ATE291911T1 (de) 2005-04-15
ATE307576T1 (de) 2005-11-15
MA26466A1 (fr) 2004-12-20
US8329214B2 (en) 2012-12-11
TNSN98009A1 (fr) 2005-03-15
US20080063726A1 (en) 2008-03-13
NO993519L (no) 1999-09-16
US20070184103A1 (en) 2007-08-09
CY2560B1 (fr) 2008-07-02
DK2050445T3 (da) 2013-09-08
ES2195308T3 (es) 2003-12-01
CN1496738A (zh) 2004-05-19
ATE233556T1 (de) 2003-03-15
FR2758459B1 (fr) 1999-05-07
EP1273294B1 (fr) 2005-10-26
PT952829E (pt) 2003-07-31
US20020168413A1 (en) 2002-11-14
EP1273294A1 (fr) 2003-01-08
HK1023071A1 (en) 2000-09-01
DZ2398A1 (fr) 2003-06-04

Similar Documents

Publication Publication Date Title
AR011411A1 (es) Composicion de fenofibrato de liberacion inmediata, metodo para prepararla y suspension de fenofibrato en forma micronizada.
AR040684A1 (es) Forma de dosificacion solida recubierta y metodo de preparacion de la misma
ES2120430T3 (es) Pastillas o comprimidos que contienen material genetico y portador inerte para los mismos y metodo para su preparacion.
AR018637A1 (es) Un fertilizante de liberacion controlada y un procedimiento para su preparacion
AR018573A1 (es) Metodo para microencapsular una sustancia solida y microcapsula de una sustancia solida que tiene una capa intermedia obtenida por el mismo
JP2007536261A5 (es)
WO2001013891A3 (en) Modulation of release from dry powder formulations
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
CY1105051T1 (el) Παρασκευασμα σε μορφη υμενιου για τη διφασικη απελευθερωση ουσιων με φαρμακολογικη δραση ή αλλων ουσιων
BR8901900A (pt) Sistema para liberacao de uma substancia ativa para a atmosfera,matrizes e processo para formacao de um reservatorio de liberacao de substancia ativa
JP2003512395A5 (es)
CO5560533A2 (es) Preparacion de una composicion farmaceutica de liberacion sostenida
AR010875A1 (es) Tableta para liberacion controlada de agentes activos.
DE50103340D1 (de) Verfahren zur herstellung aktivstoffhaltiger kapseln mit ultradünner wandschicht
DE69209080D1 (de) Pharmazeutische zusammemsetzungen mit verzoegerter freigabe
ES2187049T3 (es) Dispersion acuosa de laca en polvo, procedimiento para su preparacion y utilizacion de la dispersion de laca en polvo obtenida.
CA2514446A1 (en) Composition comprising a mixture of active principles, and method of preparation
JP2001512149A5 (es)
AR001879A1 (es) Método para producir un artículo rigido sinterizado de metales duros y el artículo resultante
JP4719354B2 (ja) 個別層から成る積層体の製造方法
US20040214002A1 (en) Polymer films
DE60228129D1 (de) Pharmazeutische zusammensetzung enthaltend eine wasser/öl/wasser doppelte mikroemulsion in einem festen träger
ATE285754T1 (de) Pharmazeutische zusammensetzung mit lyophilisierten lyposomen welche einen unlöslichen aktiven wirkstoff einschliessen, verfahren zu dessen herstellung
ES2172030T3 (es) Cuerpo de varias capas, respirable, de estructura laminar/no tejido, elastomero, microporoso y metodo para su fabricacion.
DE60320661D1 (de) System mit kontrollierter freisetzung bioaktiver wirkstoffe

Legal Events

Date Code Title Description
FC Refusal
FC Refusal